THE HAMOUI FOUNDATION

LUNGEVITY
Transforming Lung Cancer

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

IMPORTANT NOTES TO READ BEFORE PROCEEDING

The Hamoui Foundation is partnering with LUNGevity Foundation ("LUNGevity") to issue an RFA specific to the study of RET-positive lung cancer.

LUNGevity Foundation advises applicants to read the entire RFA, including eligibility requirements and other terms and conditions, before starting an application. Any applicant who is deemed ineligible for this award and/or does not follow the instructions for preparing the application will be disqualified and the application not reviewed.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer uses a **two-step application process**. An applicant must first submit a letter of intent (LOI). Only a subset of applicants will be invited to submit a full application after the LOIs are reviewed. This award application process will be managed through proposalCENTRAL.

Important Dates:

- February 16, 2024: Letter of Intent (LOI) deadline
- May 15, 2024: Full application deadline
- Late Summer 2024: Award notifications made
- November 1, 2024: Awards begin

Detailed instructions for submitting a Hamoui Foundation/LUNGevity Clinical Research Award application begin on page12.

THE HAMOUI FOUNDATION

The Hamoui Foundation is a private family foundation based in Southern California. The Foundation's goal is to focus efforts on a select number of key initiatives to create visible step changes in the organizations they support. The Foundation aims to create sustainable benefit through the establishment of endowments that provide ongoing funding. While the focus is on creating substantial changes for select projects, the Foundation does not underestimate the power of supporting selective local non-profit organization in their community. With the increasing crises in the Middle East, it has been a personal interest for them to aid and support families who have been displaced or were affected by the economic crises in the area. Since the establishment in 2010, the Foundation has gifted over $21.5 million to support progress in areas of medical research, education, community nonprofit organizations, and the fight against hunger and poverty.
For more information about The Hamoui Foundation, please visit https://www.hamouifoundation.org

LUNGEVITY FOUNDATION

LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and effective treatment of lung cancer. LUNGevity's mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of

lung cancer, early intervention in the disease progression, and treatments, including targeted therapy and immunotherapy. LUNGevity focuses on translational science. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.

FUNDING OPPORTUNITY DESCRIPTION

Goal of the program

To fund high-impact research that seeks to transform the future for patients diagnosed with RET-positive lung cancer by changing RET-positive lung cancer into a chronic or curable condition.

Overview

The Hamoui Foundation is partnering with LUNGevity Foundation to support RET-positive non-small cell lung cancer research. The Hamoui Foundation will leverage LUNGevity's scientific review process as well as fund its research through LUNGevity. This research will address critical unanswered questions in the RET space. This award program is separate from, and in addition to, LUNGevity's Career Development, Early Detection, and Targeted Therapeutics award programs and aligns well with LUNGevity's mission of funding high-impact science.

The recipient(s) of the award will be announced no earlier than Late Summer 2024. The award(s) may be for a maximum of $250,000 per year for two years, for a total award of $500,000. The award funds will be disbursed in annual payments of $250,000.

HAMOUI FOUNDATION/LUNGEVITY CLINICAL RESEARCH AWARD PROGRAM REQUIREMENTS

The research funded through this program is expected to have a direct impact on the outcomes of patients with advanced RET-positive lung cancer, but innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission. Projects looking to understand psychosocial aspects of a RET-positive lung cancer diagnosis are **not** within the scope of this RFA.

Successful applicants are required during the duration of the award term to share their research progress with the members of The Hamoui Foundation and the LUNGevity team (Scientific Advisory Board, other reviewers, and other awardees) every six months virtually as well as annually at the LUNGevity science meeting.

Scientific scope

The goal of the award is to fund impactful proposals in the RET-positive non-small cell lung cancer space **with direct clinical implications within 1-2 years after award completion** that answer the question: What treatment options are available after the current FDA-approved RET tyrosine kinase inhibitors stop working? How can patients stay longer on currently approved treatments? **Projects must be directly related to improvement of patient outcomes and ideally lead to a clinical trial.**

Potential areas of exploration include, but are not limited to, the following types of projects:

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

- Using real-world data to understand treatment sequencing and efficacy of other regimens such as novel treatments like antibody-drug conjugates and traditional treatments like immunotherapy and chemotherapy. **Note**: Funding will **not** be provided to already existing registries without significant clinical justification.
- Using real-world data to understand side effect management to prolong duration of response/keep patient on therapy.
- Funding correlative studies associated with an already-established investigator-initiated trial in the post-RET TKI space (post-selpercatinib and post-pralsetinib)

The above are suggested topics and are not meant to be prescriptive. If an applicant is unsure whether a proposed project will fit the current RFA, we encourage them to reach out to us. Final selection of the project(s) to be funded will be contingent on scientific review and availability of funds.

Eligibility

If an applicant does not currently meet an eligibility requirement, but either will meet it soon or has special circumstances that prevent it from being met, the applicant must let us know at the time the LOI is submitted. A page with the information should be attached to the back of the biosketch.

Education and Experience*:* At the time of the award term, the applicant, who must be a principal investigator for the proposed research, must:

1) hold a doctoral degree and have a faculty appointment with a university-based academic institution or a research institution that is not formally associated with a university.

2) have completed a postdoctoral training fellowship.

The applicant may be at any level of research experience and must be an independent, self-directed researcher for whom their institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities.

Geographical Restriction: The Award Program does not have any geographical restrictions. An applicant can apply from any part of the world as long as they conduct research in a nonprofit institution, as defined by country-specific laws.

Applicants are **not** required to be U.S. citizens or to be employed by a U.S. institution. **At the time of application, if an applicant is employed by a U.S. institution**, they must be a United States citizen or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card), exchange visitor (J-1), temporary worker in a specialty occupation (H-1, H-1B),

Canadian or Mexican citizen engaging in professional activities (TC or TN), or temporary worker with extraordinary abilities in the sciences (O-1). This applicant/awardee must be employed by a U.S. institution throughout the duration of the award term.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer 2024 Request for Application (RFA)

AWARD INFORMATION

Award Structure

An awardee may receive up to $500,000 (direct and indirect) over two years. No more than 25% of the requested budget may be used for an investigator's salary and/or fringe benefits and no more than 10% of the total award budget may be used for overhead/indirect costs. None of the requested budget may be used for permanent equipment.

Award funds may be used for the salary and fringe benefit costs of personnel other than the applicant. Fringe benefit costs may only be expended upon the stipulation that they cannot be obtained from another source.

Allowable costs for clinical trials include: expenses related to subject recruitment (such as participation incentives, subject remuneration, phlebotomy charges, etc.), clinical laboratory analyses of human subjects or their samples (such as clinical laboratory assays, imaging charges, etc.), and correlative studies. The award may be used to assist with operational costs. However, drug costs **will not** be covered. If invited to submit a full application, the applicant must provide a letter of commitment of support for the project from the pharmaceutical partner, including that they will provide the drug.

The award is subject to annual reviews and may be granted for up to two years. The second- payment is based on demonstrating satisfactory progress in the first year, as well as on the availability of funds.

Award Payment Schedule

LUNGevity will issue the first-year award payment no earlier than November 1, 2024, following receipt of fully executed agreement documents. LUNGevity will issue the payment for Year 2 following satisfactory review of Year 1 progress and financial reports. Payment for Year 2 will be made only after the awardee's funding balance has decreased to $25,000 or less.

Some of the factors considered when reviewing applications include:

- **Innovation** – Does the project address a previously uninvestigated area of RET-positive lung cancer?
- **Scientific merit and feasibility of the research plan**, including partnerships. Will the proposed research be accomplished within one year and with the proposed budget?
  Impact – How will the research findings from the project move to the clinic within 2 years and impact patients? What plans does/do the applicant(s) have for the clinical application of the findings of the project?
- **Study design and its burden on patient participation,** i.e., how difficult is it for patients to participate in the proposed study? This metric will be pertinent if a clinical trial is proposed.
- **Research environment –** Does the applicant have access to institutional resources required for the successful completion of the proposed project?
- **Appropriateness of the requested budget** to complete the proposed research project

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer 2024 Request for Application (RFA)

OTHER TERMS AND CONDITIONS

Following are the other terms and conditions that apply to the Hamoui Foundation/LUNGevity Clinical Research Award. A more detailed set of terms and conditions will be included in the agreement document for funded projects.

Animal Use

The Hamoui Foundation/LUNGevity Clinical Research Award Program allows animal use in biomedical research only when no other means of obtaining scientifically sound, valid, and useful results are available. Applicants must ensure that only the minimum number of appropriate animals required to obtain and validate results shall be used. In cases requiring the death of an animal, only the most appropriate and humane form of euthanasia shall be used consistent with the purpose of the research.

Whenever animal use is a part of The Hamoui Foundation/LUNGevity-funded research project, applicants must provide The Hamoui Foundation/LUNGevity with institutional endorsements that the research facility, its research, and its employees adhere to the appropriate animal welfare regulations in their country. In the U.S., these include:

- Animal Welfare Act
- USDA rules
- National Research Council *Guide for the Care and Use of Laboratory Animals*
- Public Health Service Policy on Humane Care and Use of Laboratory Animals

In addition, those applicants who are invited to submit a full application must include in their materials the following documents:

- Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accreditation.
- Institutional Animal Care and Use of Committee (IACUC) approval.

A project is **not** eligible for an award if the research proposal involves animals and the institution does not have accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), **or** does not hold a current Public Health Service (PHS) Animal Welfare Assurance, **or** does not have accreditation from the United States Department of Agriculture or does not have accreditation from the Institutional Animal Care and Use Committee (IACUC).

Authorized Award Holders

The Hamoui Foundation/LUNGevity Clinical Research Awards are granted only to an individual; awards are not awarded to institutions. No award may be held by or transferred to another individual.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer 2024 Request for Application (RFA)

Biohazards
Biohazards are broadly defined to be recombinant and/or infectious and tumor materials that may be deleterious to normal organisms upon controlled exposure. Research involving biohazards requires one paper copy of the appropriate institutional committee approval at the time a full application is submitted.

Carryover of Funding
Carryover of funding into the second funding period requires prior approval by The Hamoui Foundation/LUNGevity. All requests must be in writing and received by The Hamoui Foundation/LUNGevity 60 days prior to the end of the current funding period. When making the request, the awardee must indicate the amount and from what budget-line and to what budget-line the carryover monies are being applied. In the case of supplies, all items must be itemized.

Change in Budget
Requests for a change in budget that is 10% or more require prior approval by The Hamoui Foundation/LUNGevity. All requests must be in writing and received by The Hamoui Foundation/LUNGevity 60 days prior to the end of the first funding period. When requesting a change in budget, the awardee must indicate the amount and from what budget-line and to what budget-line the monies are being transferred. In the case of supplies, all items must be itemized.

Change of Institution
Transfer of The Hamoui Foundation/LUNGevity award from one institution to another requires prior approval by The Hamoui Foundation/LUNGevity. All requests must be in writing and made as soon as the awardee officially knows of the relocation. A grant may not be transferred to a laboratory, clinic, hospital, or other research institution that is not affiliated with a tax-exempt not-for-profit institution. All unexpended funds must be returned to LUNGevity within 45 days of transfer approval. A grant may not be transferred to a laboratory, clinic, hospital, or other research institution that is not affiliated with a tax-exempt not-for-profit institution.

Equal Employment Opportunity
The Hamoui Foundation/LUNGevity awards will be awarded to individuals working in institutions identified as Equal Opportunity Employers.

Equipment Purchase
None (0%) of the award budget may be used for the purchase of permanent equipment.

Equipment Repair & Service Contracts
None (0%) of the award budget may be used for repair or service contract costs for institutional equipment.

Human Subjects
Whenever human participants are a part of the The Hamoui Foundation/LUNGevity-funded research project, the following documents must be received before any award funds are released:

- A copy of the Institutional Review Board (IRB) approval (or non-U.S. equivalent) and approved patient consent forms.

- A copy of the appropriate institutional committee approval for research involving human adult stem cells or use of human fetal tissue.

If the proposed research project involves human subjects, the population sampled shall be inclusive of the general population of relevance to the scientific question posed, without restriction in regard to gender, race, age, and socioeconomic status. Proposals that intentionally restrict the population sampled must include a compelling scientific rationale for such design.

Applicants are encouraged to submit their projects to the appropriate human subjects Institutional Review Board at the time of application.

***IRB approval and approved patient consent forms must be provided before award funds will be disbursed*.**

Malpractice Liability
The Hamoui Foundation/LUNGevity will not assume responsibility for and the institution will indemnify and hold The Hamoui Foundation/LUNGevity harmless from any lawsuit, claim, judgment, damages, awards, or malpractice arising from research or investigations related to an award.

No-cost Extension
A no-cost award extension requires prior approval by The Hamoui Foundation/LUNGevity. All requests must be in writing and received by The Hamoui Foundation/LUNGevity at least 90 days prior to the award's official termination date. When making the request, the awardee must provide a detailed rationale for the extension, project expenses to date, and a detailed revised budget. Awardees may request a no-cost extension only once per award. Approval of the no-cost extension is not automatic and will only be granted in exceptional circumstances.

Other Funding
The Hamoui Foundation/LUNGevity research funds may not be awarded to duplicate any work that is being supported by other funding agencies. Partial funding from a pharmaceutical company for a phase 1 trial is encouraged. Details about additional funding sought for the same project should be provided in the full application.

Overhead/Indirect Costs
Overhead or indirect costs are permitted up to 10% of the award and are not incremental to the award. Duplication of indirect costs on subcontracts is not allowed.

Patent and Intellectual Property Policy
Inventions and discoveries from research performed during the term of the The Hamoui Foundation/LUNGevity award will be subject to the current The Hamoui Foundation/LUNGevity patent policy as well as to the patent policies of the institution where the work is performed. The LUNGevity policy is described in full on page 9.

Progress and Financial Reports
Annual written progress and financial reports (as well as presentations at the annual LUNGevity Science Meeting) are required. Interim reports are the basis for the decision to award the next

round of funding. A final progress report is also required at the conclusion of the project along with a complete financial disbursement report covering the entire award period. The financial report must reflect the award expenditures as approved by The Hamoui Foundation/LUNGevity. Unspent funds must be returned at the conclusion of the award period. In addition, any funds used for unauthorized expenditures must be returned.

Project Support Expenditures
No award shall be used for the purchase of furniture or computers, the construction or renovation of facilities, payment of honoraria or membership dues, payment for tuition, the purchase of textbooks or periodicals, or payment for secretarial support.

Preprints and Public Access Policy
Grantees are required to deposit their submitted manuscripts, and subsequent versions, via a publicly accessible preprint server (e.g., arXiv, bioRxiv, medRxiv, or another trusted disciplinary server). Preprints must be shared under an open license (CC BY). LUNGevity Foundation recognizes preprints as evidence of productivity for purposes of grant applications, reviews, and reporting.

Upon acceptance, we require electronic copies of research papers, accepted for publication in a peer-reviewed journal and supported in whole or in part by this award, to be made freely available upon publication. Grantees may comply with this policy by publishing in an open access journal, publishing in a hybrid journal with an open access option, or by making a copy of their Author Accepted Manuscript available via a trusted open repository (e.g., PubMed Central). All peer-reviewed articles must be freely available under a suitable open license, preferably the Creative Commons Attribution (CC BY) license, which permits reuse without restriction.

Publication Expenditures
The maximum amount of funds expendable for publication costs is $2,000 per year. All publication costs must directly relate to The Hamoui Foundation/LUNGevity project.

Publications and Conference Presentations
All publications and/or presentations at scientific conferences and meetings based on research conducted from this award must include a citation of The Hamoui Foundation/LUNGevity as a supporting entity as follows: “This study was supported by a grant from The Hamoui Foundation/LUNGevity Foundation.” Reprints of abstracts, manuscripts, or other articles that reflect research done after award acceptance must be submitted to The Hamoui Foundation/LUNGevity.

Supply Purchases
Upon conclusion of the award, supplies purchased with award funds become the property of the institution at which the work was done.

Tobacco-Funded Research
The Hamoui Foundation/LUNGevity will not provide research or other funding to applicants who have received direct funding or funding from agencies of the tobacco industry.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

Travel Expenditures

The maximum amount of funds expendable for travel is $1,500 per year per investigator. These travel funds can only be used if the work related to this grant is being presented in poster/oral presentation/abstract form. Travel to LUNGevity meetings is paid directly by the Foundation and should not be included in the $3,000.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

THE HAMOUI FOUNDATION/LUNGEVITY FOUNDATION PATENT AND INTELLECTUAL PROPERTY POLICY

a. All inventions or intellectual property made with support in whole or in part by research or training grants or awards from LUNGEVITY must be reported at the earliest practical time to the Research and Program Services Division. The grantee institution or individual awardee agrees to notify LUNGEVITY immediately of the decision to apply for letters patent or other legal protection for intellectual property, and to consider seriously and in good faith any comments or objections LUNGEVITY may have concerning such applications. LUNGEVITY agrees to keep all information confidential and to not release any information relating to such inventions, intellectual property or applications. All patenting expenses shall be borne by the grantee institution or individual awardee unless the intellectual property is ceded to LUNGEVITY (see paragraphs b and c).

b. Title to any invention or intellectual property shall reside in the grantee institution to the extent that such title is claimed by the institution under its patent policy or procedure and paragraphs c-e shall apply. If a grantee institution has no established patent policy or procedure for administering inventions or intellectual property, or if the institutional patent policy or procedure does not claim rights for the institution or individual inventor, then LUNGEVITY shall have the right to determine the disposition of invention or intellectual property rights and paragraphs c-d shall not apply.

c. No patent, patent application or other type of protection shall be abandoned without first notifying the Research and Program Services Division. At such time, the grantee institution and individual awardee shall give LUNGEVITY the opportunity to take title to the invention or other intellectual property.

d. The grantee institution shall agree that when it licenses any invention or intellectual property it will obligate the licensee as follows: The licensee agrees to exert its best efforts to commercialize or cause to be commercialized the invention or intellectual property as rapidly as practical, consistent with sound and reasonable business practices and judgment. In the event that the licensee has failed to commercialize the invention or intellectual property within the number of years determined to be reasonable for the invention or intellectual property, the grantee institution upon conferring with LUNGEVITY shall have the right to convert an exclusive license to a non-exclusive license or to terminate a non-exclusive license. If the licensee or grantee institution has an ongoing and active research, development, manufacturing, marketing or licensing program as appropriately directed toward the production and sale of the invention or intellectual property, the same would be deemed to be sufficient evidence that the licensee or grantee institution has commercialized the invention or intellectual property.

e. LUNGEVITY and The Hamoui Foundation reserve the right to public acknowledgment for inventions or intellectual property resulting from support by LUNGEVITY and The Hamoui Foundation; however,

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

LUNGEVITY and The Hamoui Foundation name and logo may not be used in association with an invention or intellectual property without prior approval of LUNGEVITY and The Hamoui Foundation.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer 2024 Request for Application (RFA)

APPLICATION INSTRUCTIONS AND TIMELINE

Templates and detailed instructions for required information/materials can be found at https://proposalcentral.com. Be sure to read those instructions in case any instructions were changed, added, or deleted after this RFA was issued.

Letter of Intent (LOI)
The letter of intent must include:

• A **narrative** that includes:

1. **Rationale** for the project with details on how the project will impact clinical care of RET-positive lung cancer patients
2. Planned **specific aims** (may be modified slightly if invited to submit a full application)
3. Brief statement of the **overall experimental approach**
4. Brief statement describing the **clinical context** in which therapeutic strategy will be used
5. Brief statement of clinical translatability and timeframe of translation
6. Brief statement of the **quantitative metrics/performance** that the approach should achieve to show clinical utility
7. A few pertinent **references**

The narrative should be typed in Arial 11-point type, single-spaced, with .5" margins. Identifying information, per the template, must be included at the top of each page. The narrative should not exceed a total of **three pages**, including the references. **Your LOI will not be considered if these instructions are not followed.**

The following items should be included as part of the LOI:

- An NIH **biosketch** (OMB No. 0925-0001 and 0925-0002) of the applicant only. Double-check that the information included is current and thorough. **We will not be contacting you to clarify any information.**

- If a non-citizen, **proof of visa immigration status**, as described under "Award Eligibility." This should be attached to the end of the biosketch.

No budget information or other supporting materials should be included with the LOI. A sponsoring institution signature is not required.

Templates and detailed instructions can be found at https://proposalcentral.com.

Letters of Intent are due **by February 16, 2024 (11:59pm EST)** via proposalCENTRAL. Extensions will not be given. Once an LOI has been submitted it cannot be changed.

Applicants will be notified by email no later than **March 25, 2024,** whether they will be invited to submit full application. LUNGevity will **not** provide feedback regarding results of the review of any Letter of Intent submitted.

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

Full Application

Only invited applicants may prepare and submit a full application. Instructions for how to proceed will accompany the invitation. Among other materials, the full application must include:

A **narrative** to include these components:

1. **Background**: Present the ideas and reasoning behind the proposed research; include relevant literature citations. Describe previous experience most pertinent to this application.
2. **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
3. **Specific Aims:** Concisely explain the project's specific aims. Please include a description on whether and how you propose to include biospecimens from RET-positive lung cancer patients in your proposed experiments.
4. **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. **If proposing a clinical trial,** please include a detailed sample size justification and any statistical analysis you propose to use. Also, clearly describe impact on patient participation (for example, number and frequency of blood draws and biopsies, number of clinical visits, etc.)
5. **Clinical Translatability:** Please describe how you propose to translate the findings of this research to the clinic. Share specifics about potential clinical collaborators, patient population who will benefit from clinical translation, timeline, etc.
6. **Statistical analysis plan:** A detailed statistical analysis plan is required for all applications and is limited to 1 single-spaced page. The analysis plan should define the primary objectives, study design, and planned analyses supporting the study hypotheses. Justification of the proposed sample size or number of patient samples to be analyzed should be stated and include all parameters required for calculation: the type I error rate, power, and target effect size. Detail regarding analysis methods, groups to be compared, and other assumptions made (for example, regarding accrual rates, follow up, etc.) should also be included. Ideally, the applicant will collaborate with a biostatistician on their grant proposal, including this analysis plan. In the event that methods from other quantitative sciences are planned (for example, bioinformatics or computational biology), it is recommended that the applicant also collaborate with experts from those respective fields to develop their application and analysis plan. It is recommended that candidates use a full page of the application for their statistical analysis plan.
7. **Patient impact statement** – How will the research findings from the project move to the clinic within 1-2 years of completing the award and impact patients? What plans does/do the applicant(s) have for the clinical application of the findings of the project?
8. **Other funds available to support the proposed project**, such as funds provided by drug companies for part of a clinical trial (as applicable)
9. **References**

The narrative should be typed in Arial 11-point type, single-spaced, with .5" margins. Clarity and brevity are highly desirable qualities in an application. The narrative should not exceed a total of 9 + 1 page for statistical analysis plan (total **10 pages,** excluding the references).

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer 2024 Request for Application (RFA)

In addition to the narrative, the following items should also be included with the application package:

- **NIH biosketches** (OMB No. 0925-0001 and 0925-0002) of the applicant and key personnel. The biosketches should be limited to five pages each.

- **Budget information** by six-month period, along with a justification

- **Other Support:** For the applicant and any co-PIs. This should include the value of the support, including current, and pending.
- A **letter of support** from the pharmaceutical partner that includes confirmation that the partners will provide the drug, if the proposed project is a clinical trial.

- **The following documents**, if relevant:

    - a copy of the documents listed in the "Animal Use" section
    - a copy of the biohazard document named in the "Biohazards" section
    - a copy of proof of visa immigrant status as described in the "Award Eligibility" section of the RFA (this may be attached at the end of the applicant's biosketch)

Do **not** include reprints of your previous publications.

Templates and more detailed instructions for all of the above materials and any other materials that must be included can be found at https://proposalCENTRAL.com.

Full applications must be submitted via proposalCENTRAL **by May 15, 2024 at 11:59pm EST.** Extensions will not be granted. Once a full application has been submitted, it cannot be changed.Applicants will be notified of award decisions by email in **Late Summer 2024**. Review comments will be provided for full applications only.

Awardees will receive a formal agreement document at the time of or soon after award notification. This must be signed by both the awardee and an authorized representative of the sponsoring institution and then returned before any funds will be released. Funds will be released no earlier than **November 1, 2024.**

APPLICATION ASSISTANCE
For answers to questions regarding programs, eligibility, policies, terms and conditions, or instructions for the letter of intent or full application, please contact:

Jody Roosevelt
Research Program Coordinator
jroosevelt@LUNGevity.org

For help with proposalCENTRAL, please contact:

The Hamoui Foundation/LUNGevity Clinical Research Award Program for RET-positive Lung Cancer
2024 Request for Application (RFA)

proposalCENTRAL Help Desk
pcsupport@altum.com
800-875-2562